Arnold J. Greenspon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arnold J. Greenspon has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Reginald T. Ho
Department of Medicine, Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
6 shared publications - Behzad B. Pavri
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
5 shared publications Reginald T. Ho
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
5 shared publications- Daniel Robert Frisch
Department of Medicine Rutgers Robert Wood Johnson Medical School New Brunswick NJ
4 shared publications Behzad B. Pavri
2 shared publicationsDaniel R. Frisch
2 shared publications
Latest Publications
- Open Access
Reimagining Cryptogenic Stroke Care: Collaborative Care and Inpatient Insertable Cardiac Monitors for Detection of Atrial Fibrillation
Background: Atrial fibrillation (AF) is a known risk factor of ischemic stroke and AF-related stroke is twice more likely to be fatal. Long-term cardiac rhythm monitoring using insertable cardiac monitors (ICMs) has greater diagnostic yield compared to conventional monitoring in detecting AF, and clinical utility of ICMs is established in cryptogenic stroke, strokes due to large artery atherosclerosis and small vessel disease. A registry-based study was conducted to evaluate inpatient implantation of ICMs and feasibility of vascular and interventional neurologists as implanters using novel collaborative clinical care pathway for cryptogenic stroke. Methods: Multiyear data from a hospital-based registry at a comprehensive stroke center was reviewed to evaluate inpatient ICM implantation and test feasibility of vascular and interventional neurologists/VIN as implanters of ICMs together with cardiology using a novel collaborative care pathway. Reviewed data included number of ICMs, implantation trend, inpatient vs. outpatient setting, time to ICM implantation, inpatient workflow including defined roles of team members, and AF detection rate. Results: Total of 290 ICMs for cryptogenic stroke were implanted when patients where in the hospital and 78 as outpatient after discharge during the study period of 3 years. The majority of inpatient ICM implants were performed by VIN (n=181) and ICM use for cryptogenic stroke increased by 130%. Average time to inpatient ICM implant was 4.1 days with 77% in 5 and 95.5% within 10 days post-stroke. Average time to out-patient ICM placement was 57 days. AF detection rate of 36.5% was noted at 24 months with a collaborative care pathway. Discussion: Inpatient implantation of ICMs is feasible and was performed safely and efficiently by VIN together with cardiology using a collaborative care pathway. Increase in utilization of ICMs and higher AF detection rates were noted. Findings support innovative efforts to improve access and close the gaps in delivery of cryptogenic stroke care to ultimately reduce the secondary stroke burden. Clinical Perspective: Direct inpatient implantation of ICMs in cryptogenic stroke allows increased rates of early long-term cardiac rhythm monitoring and detection of AF. Collaborative clinical practice with inpatient ICM implantation by vascular and interventional neurologists is feasible and safe. This novel approach could potentially increase access to cardiac rhythm monitoring and exemplify patient-centered care.
Open AccessReimagining Cryptogenic Stroke Care: Collaborative Care and Inpatient Insertable Cardiac Monitors for Detection of Atrial Fibrillation
Background: Atrial fibrillation (AF) is a known risk factor of ischemic stroke and AF-related stroke is twice more likely to be fatal. Long-term cardiac rhythm monitoring using insertable cardiac monitors (ICMs) has greater diagnostic yield compared to conventional monitoring in detecting AF, and clinical utility of ICMs is established in cryptogenic stroke, strokes due to large artery atherosclerosis and small vessel disease. A registry-based study was conducted to evaluate inpatient implantation of ICMs and feasibility of vascular and interventional neurologists as implanters using novel collaborative clinical care pathway for cryptogenic stroke. Methods: Multiyear data from a hospital-based registry at a comprehensive stroke center was reviewed to evaluate inpatient ICM implantation and test feasibility of vascular and interventional neurologists/VIN as implanters of ICMs together with cardiology using a novel collaborative care pathway. Reviewed data included number of ICMs, implantation trend, inpatient vs. outpatient setting, time to ICM implantation, inpatient workflow including defined roles of team members, and AF detection rate. Results: Total of 290 ICMs for cryptogenic stroke were implanted when patients where in the hospital and 78 as outpatient after discharge during the study period of 3 years. The majority of inpatient ICM implants were performed by VIN (n=181) and ICM use for cryptogenic stroke increased by 130%. Average time to inpatient ICM implant was 4.1 days with 77% in 5 and 95.5% within 10 days post-stroke. Average time to out-patient ICM placement was 57 days. AF detection rate of 36.5% was noted at 24 months with a collaborative care pathway. Discussion: Inpatient implantation of ICMs is feasible and was performed safely and efficiently by VIN together with cardiology using a collaborative care pathway. Increase in utilization of ICMs and higher AF detection rates were noted. Findings support innovative efforts to improve access and close the gaps in delivery of cryptogenic stroke care to ultimately reduce the secondary stroke burden. Clinical Perspective: Direct inpatient implantation of ICMs in cryptogenic stroke allows increased rates of early long-term cardiac rhythm monitoring and detection of AF. Collaborative clinical practice with inpatient ICM implantation by vascular and interventional neurologists is feasible and safe. This novel approach could potentially increase access to cardiac rhythm monitoring and exemplify patient-centered care.
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (5) , e011740
Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients
Background: Cardiac implantable electronic device (CIED) infection has a high mortality. Previous investigations showed reduced postoperative infections using skin preparation with chlorhexidine, preoperative intravenous antibiotics, and a TYRX-a antibacterial envelope. The additional benefit of antibiotic pocket wash and postoperative antibiotics has not been systematically studied. Methods: The ENVELOPE trial (A Randomized trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients) was a prospective, multicenter, randomized, controlled trial enrolling patients undergoing CIED procedures with ≥2 risk factors for infection. The control arm received standard chlorhexidine skin preparation, intravenous antibiotics, and the TYRX-a antibiotic envelope. The study arm received pocket wash (500 mL antibiotic solution) and postoperative antibiotics for 3 days along with the prophylactic control measures. The primary end point was CIED infection and system removal at 6 months. Results: One thousand ten subjects (505 per arm) were enrolled and randomized. Patients were seen in person for a wound check with digital photo 2 weeks postimplant and at 3 and 6 months. CIED infection rate was low in both groups (1.0% control arm and 1.2% study arm, P =0.74). In the 11 subjects with infection and system removal, the time to study end point was 107±92 days with a PADIT (Prevention of Arrhythmia Device Infection Trial) score of 7.4 and a 64% 1-year mortality. Prior history of CIED infection independently predicted CIED system removal at 6 months in all subjects (odds ratio, 9.77, P =0.004). Of 11 infections requiring system removal, 5 were in the setting of pocket hematoma. Conclusions: The use of antibiotic pocket irrigation and postoperative oral antibiotics provides no additional benefit to the prophylactic measures of chlorhexidine skin preparation, preoperative intravenous antibiotics, and an antibiotic envelope in reducing CIED infection. Postoperative hematoma is a major risk factor for infection, driven by the use of antiplatelet and anticoagulant medications. The strongest predictor of CIED removal at 6 months, regardless of intervention, was prior CIED infection. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02809131.
- 1 May 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (5) , e011740
Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients
Background: Cardiac implantable electronic device (CIED) infection has a high mortality. Previous investigations showed reduced postoperative infections using skin preparation with chlorhexidine, preoperative intravenous antibiotics, and a TYRX-a antibacterial envelope. The additional benefit of antibiotic pocket wash and postoperative antibiotics has not been systematically studied. Methods: The ENVELOPE trial (A Randomized trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients) was a prospective, multicenter, randomized, controlled trial enrolling patients undergoing CIED procedures with ≥2 risk factors for infection. The control arm received standard chlorhexidine skin preparation, intravenous antibiotics, and the TYRX-a antibiotic envelope. The study arm received pocket wash (500 mL antibiotic solution) and postoperative antibiotics for 3 days along with the prophylactic control measures. The primary end point was CIED infection and system removal at 6 months. Results: One thousand ten subjects (505 per arm) were enrolled and randomized. Patients were seen in person for a wound check with digital photo 2 weeks postimplant and at 3 and 6 months. CIED infection rate was low in both groups (1.0% control arm and 1.2% study arm, P =0.74). In the 11 subjects with infection and system removal, the time to study end point was 107±92 days with a PADIT (Prevention of Arrhythmia Device Infection Trial) score of 7.4 and a 64% 1-year mortality. Prior history of CIED infection independently predicted CIED system removal at 6 months in all subjects (odds ratio, 9.77, P =0.004). Of 11 infections requiring system removal, 5 were in the setting of pocket hematoma. Conclusions: The use of antibiotic pocket irrigation and postoperative oral antibiotics provides no additional benefit to the prophylactic measures of chlorhexidine skin preparation, preoperative intravenous antibiotics, and an antibiotic envelope in reducing CIED infection. Postoperative hematoma is a major risk factor for infection, driven by the use of antiplatelet and anticoagulant medications. The strongest predictor of CIED removal at 6 months, regardless of intervention, was prior CIED infection. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02809131.
- 1 December 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (12) , 2215-2218
An unusual incessant long RP tachycardia—What is the mechanism?
- 1 December 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (12) , 2215-2218
An unusual incessant long RP tachycardia—What is the mechanism?
- 28 August 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (10) , 1735-1737
Dual‐chamber pacing with variable AV delays: What is the mechanism?
- 28 August 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (10) , 1735-1737
Dual‐chamber pacing with variable AV delays: What is the mechanism?
- Open Access
- 23 March 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (9) , 1446-1455
Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score
The Prevention of Arrhythmia Device Infection Trial (PADIT) infection risk score, developed based on a large prospectively collected data set, identified five independent predictors of cardiac implantable electronic device (CIED) infection. We performed an independent validation of the risk score in a data set extracted from U.S. healthcare claims. Retrospective identification of index CIED procedures among patients aged ≥18 years with at least one record of a CIED procedure between January 2011 and September 2014 in a U.S health claims database. PADIT risk factors and major CIED infections (with system removal, invasive procedure without system removal, or infection-attributable death) were identified through diagnosis and procedure codes. The data set was randomized by PADIT score into Data Set A (60%) and Data Set B (40%). A frailty model allowing multiple procedures per patient was fit using Data Set A, with PADIT score as the only predictor, excluding patients with prior CIED infection. A data set of 54 042 index procedures among 51 623 patients with 574 infections was extracted. Among patients with no history of prior CIED infection, a 1 unit increase in the PADIT score was associated with a relative 28% increase in infection risk. Prior CIED infection was associated with significant incremental predictive value (HR 5.66, P < 0.0001) after adjusting for PADIT score. A Harrell’s C-statistic for the PADIT score and history of prior CIED infection was 0.76. The PADIT risk score predicts increased CIED infection risk, identifying higher risk patients that could potentially benefit from targeted interventions to reduce the risk of CIED infection. Prior CIED infection confers incremental predictive value to the PADIT score.
- 23 March 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 23 (9) , 1446-1455
Open AccessUse of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score
The Prevention of Arrhythmia Device Infection Trial (PADIT) infection risk score, developed based on a large prospectively collected data set, identified five independent predictors of cardiac implantable electronic device (CIED) infection. We performed an independent validation of the risk score in a data set extracted from U.S. healthcare claims. Retrospective identification of index CIED procedures among patients aged ≥18 years with at least one record of a CIED procedure between January 2011 and September 2014 in a U.S health claims database. PADIT risk factors and major CIED infections (with system removal, invasive procedure without system removal, or infection-attributable death) were identified through diagnosis and procedure codes. The data set was randomized by PADIT score into Data Set A (60%) and Data Set B (40%). A frailty model allowing multiple procedures per patient was fit using Data Set A, with PADIT score as the only predictor, excluding patients with prior CIED infection. A data set of 54 042 index procedures among 51 623 patients with 574 infections was extracted. Among patients with no history of prior CIED infection, a 1 unit increase in the PADIT score was associated with a relative 28% increase in infection risk. Prior CIED infection was associated with significant incremental predictive value (HR 5.66, P < 0.0001) after adjusting for PADIT score. A Harrell’s C-statistic for the PADIT score and history of prior CIED infection was 0.76. The PADIT risk score predicts increased CIED infection risk, identifying higher risk patients that could potentially benefit from targeted interventions to reduce the risk of CIED infection. Prior CIED infection confers incremental predictive value to the PADIT score.
- 16 February 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (6) , 1130-1132
Ventricular tachycardia induced by a backup pacing stimulus in a patient with a dual chamber pacemaker with AutoCapture
- 16 February 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (6) , 1130-1132
Ventricular tachycardia induced by a backup pacing stimulus in a patient with a dual chamber pacemaker with AutoCapture
- 21 June 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (9) , 992-999
Atrial fibrillation post central retinal artery occlusion: Role of implantable loop recorders
Objective This study evaluated the risk of subclinical atrial fibrillation (AF) in patients with central retinal artery occlusion (CRAO) compared to those with cryptogenic stroke using implantable loop recorders (ILR). Methods We conducted a retrospective analysis of 273 consecutive patients who had ILRs inserted at our institution for either cryptogenic stroke (n = 227) or CRAO (n = 46). Our primary endpoint was a time to event analysis for the new diagnosis of AF by ILR. Univariable and multivariable Cox proportional hazard models were used to determine the predictors of time‐to‐AF. Results A total of 64 patients were found to have newly diagnosed AF by remote monitoring of the ILR. AF was detected in 57 of 227 (25%) cryptogenic stroke patients by the end of a maximum 5.1 years follow‐up and in 7 of 46 (15%) CRAO patients by the end of a maximum 3.6year follow‐up (p = .215, log‐rank test). The Kaplan‐Meier estimates for freedom from AF was 59.4% for CRAO and 66.6% for cryptogenic stroke (p = NS, log‐rank test). Baseline variables predicting AF included older patients, higher CHADS2VASC score, longer PR interval on initial EKG evaluation and mitral annular calcification (MAC) on transthoracic echocardiogram. Conclusions Patients with CRAO are at risk for subclinical AF, similar to those with cryptogenic stroke. Long term monitoring to detect AF may lead to changes in pharmacotherapy to reduce the risk for subsequent stroke. This article is protected by copyright. All rights reserved
- 21 June 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (9) , 992-999
Atrial fibrillation post central retinal artery occlusion: Role of implantable loop recorders
Objective This study evaluated the risk of subclinical atrial fibrillation (AF) in patients with central retinal artery occlusion (CRAO) compared to those with cryptogenic stroke using implantable loop recorders (ILR). Methods We conducted a retrospective analysis of 273 consecutive patients who had ILRs inserted at our institution for either cryptogenic stroke (n = 227) or CRAO (n = 46). Our primary endpoint was a time to event analysis for the new diagnosis of AF by ILR. Univariable and multivariable Cox proportional hazard models were used to determine the predictors of time‐to‐AF. Results A total of 64 patients were found to have newly diagnosed AF by remote monitoring of the ILR. AF was detected in 57 of 227 (25%) cryptogenic stroke patients by the end of a maximum 5.1 years follow‐up and in 7 of 46 (15%) CRAO patients by the end of a maximum 3.6year follow‐up (p = .215, log‐rank test). The Kaplan‐Meier estimates for freedom from AF was 59.4% for CRAO and 66.6% for cryptogenic stroke (p = NS, log‐rank test). Baseline variables predicting AF included older patients, higher CHADS2VASC score, longer PR interval on initial EKG evaluation and mitral annular calcification (MAC) on transthoracic echocardiogram. Conclusions Patients with CRAO are at risk for subclinical AF, similar to those with cryptogenic stroke. Long term monitoring to detect AF may lead to changes in pharmacotherapy to reduce the risk for subsequent stroke. This article is protected by copyright. All rights reserved
- 19 August 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (10) , 1331-1339
Cardiovascular implantable electronic device infections due to enterococcal species: Clinical features, management, and outcomes
Background: Enterococcal cardiovascular implantable electronic device (CIED) infections are not well characterized.Methods: Data from the Multicenter Electrophysiologic Device Infection Cohort, a prospective study of CIED infections, were used for descriptive analysis of adults with enterococcal CIED infections.Results: Of 433 patients, 21 (4.8%) had enterococcal CIED infection. Median age was 71 years. Twelve patients (57%) had permanent pacemakers, five (24%) implantable cardioverter defibrillators, and four (19%) biventricular devices. Median time from last procedure to infection was 570 days. CIED‐related bloodstream infections occurred in three patients (14%) and 18 (86%) had infective endocarditis (IE), 14 (78%) of which were definite by the modified Duke criteria. IE cases were classified as follows: valvular IE, four; lead IE, eight; both valve and lead IE, six. Vegetations were demonstrated by transesophageal echocardiography in 17 patients (81%). Blood cultures were positive in 19/19 patients with confirmed results. The most common antimicrobial regimen was penicillin plus an aminoglycoside (33%). Antibiotics were given for a median of 43 days. Only 14 patients (67%) underwent device removal. There was one death during the index hospitalization with four additional deaths within 6 months (overall mortality 24%). There were no relapses.Conclusions: Enterococci caused 4.8% of CIED infections in our cohort. Based on the late onset after device placement or manipulation, most infections were likely hematogenous in origin. IE was the most common infection syndrome. Only 67% of patients underwent device removal. At 6 months follow‐up, no CIED infection relapses had occurred, but overall mortality was 24%.
- 19 August 2019
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 42 (10) , 1331-1339
Cardiovascular implantable electronic device infections due to enterococcal species: Clinical features, management, and outcomes
Background: Enterococcal cardiovascular implantable electronic device (CIED) infections are not well characterized.Methods: Data from the Multicenter Electrophysiologic Device Infection Cohort, a prospective study of CIED infections, were used for descriptive analysis of adults with enterococcal CIED infections.Results: Of 433 patients, 21 (4.8%) had enterococcal CIED infection. Median age was 71 years. Twelve patients (57%) had permanent pacemakers, five (24%) implantable cardioverter defibrillators, and four (19%) biventricular devices. Median time from last procedure to infection was 570 days. CIED‐related bloodstream infections occurred in three patients (14%) and 18 (86%) had infective endocarditis (IE), 14 (78%) of which were definite by the modified Duke criteria. IE cases were classified as follows: valvular IE, four; lead IE, eight; both valve and lead IE, six. Vegetations were demonstrated by transesophageal echocardiography in 17 patients (81%). Blood cultures were positive in 19/19 patients with confirmed results. The most common antimicrobial regimen was penicillin plus an aminoglycoside (33%). Antibiotics were given for a median of 43 days. Only 14 patients (67%) underwent device removal. There was one death during the index hospitalization with four additional deaths within 6 months (overall mortality 24%). There were no relapses.Conclusions: Enterococci caused 4.8% of CIED infections in our cohort. Based on the late onset after device placement or manipulation, most infections were likely hematogenous in origin. IE was the most common infection syndrome. Only 67% of patients underwent device removal. At 6 months follow‐up, no CIED infection relapses had occurred, but overall mortality was 24%.
- 1 December 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (12) , 1889-1890
Termination of a narrow complex tachycardia by a single extrastimulus: What is the mechanism?
- 1 December 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (12) , 1889-1890
Termination of a narrow complex tachycardia by a single extrastimulus: What is the mechanism?
- 17 April 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (9) , 1372-1377
Clinical and electrophysiological characteristics of patients with paroxysmal intra-His block with narrow QRS complexes
- 17 April 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (9) , 1372-1377
Clinical and electrophysiological characteristics of patients with paroxysmal intra-His block with narrow QRS complexes